KROS Earnings & Financial Statements
Keros Therapeutics, Inc.
$11.83
+$0.19(+1.63%)
56
Overall
80
Value
45
Tech
44
Quality
Market Cap
$230.79M
Volume
33.13K
52W Range
$9.69 - $22.55
Target Price
$18.86
KROS earnings and financial statements: Keros Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KROS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $244.06M | $3.55M | $151.0K | - | $20.10M |
| Operating income | $67.57M | -$210.83M | -$169.94M | -$114.79M | -$56.37M |
| EBITDA | $95.82M | -$184.00M | -$150.63M | -$103.06M | -$56.35M |
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M | -$58.74M |
| EPS (diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $338.02M | $615.89M | $370.02M | $306.78M | $255.25M |
| Total liabilities | $34.89M | $44.33M | $37.81M | $29.36M | $12.08M |
| Shareholders’ equity | $303.13M | $571.55M | $332.21M | $277.42M | $243.17M |
| Cash and equivalents | $287.42M | $559.93M | $331.15M | $279.05M | $230.04M |
| Long-term debt | $14.47M | $16.88M | $13.44M | $12.81M | $231.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $107.50M | -$160.87M | -$124.51M | -$70.06M | -$62.15M |
| Capital expenditure | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M |
| Free cash flow | $105.95M | -$162.80M | -$126.97M | -$71.30M | -$63.17M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KROS | $11.83 | +1.6% | 33.13K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Keros Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW